Schedule 13G ownership disclosure

ALNYLAM PHARMACEUTICALS INC COM

Security class unavailable · CUSIP: 02043Q107

Event date: 2018-04-30

Legacy cover-page extraction is best effort and may not include every reporting person.

Filing-level shares
10,706,819
Percent of class
10.6900%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000902219-18-000447
Form type
SC 13G/A
Filer
ALNYLAM PHARMACEUTICALS, INC.
CIK
CIK 1178670
Filed
May 10, 2018
Reporting period
Apr 30, 2018
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub